TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01758471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide
Description: glipizide 5mg per pill 5mg tid p.o. for 3 month
Study: NCT04511208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling Vest
Description: Evaluate that wearing a cooling vest during surgery reduces surgeons' mean-body temperature and preserves their cognitive performance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling Vest
Description: Evaluate that wearing a cooling vest during surgery reduces surgeons' mean-body temperature and preserves their cognitive performance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling Vest
Description: Evaluate that wearing a cooling vest during surgery reduces surgeons' mean-body temperature and preserves their cognitive performance.
Study: NCT01225263

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo pills, taken twice daily for 6 months
Study: NCT04511208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling Vest
Description: Evaluate that wearing a cooling vest during surgery reduces surgeons' mean-body temperature and preserves their cognitive performance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Without cooling vest
Description: Evaluate surgeons' mean-body temperature and cognitive performance without cooling vest.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Without cooling vest
Description: Evaluate surgeons' mean-body temperature and cognitive performance without cooling vest.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Without cooling vest
Description: Evaluate surgeons' mean-body temperature and cognitive performance without cooling vest.
Study: NCT01706679

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vehicle (PBS)
Study: NCT03758326

Intervention type: OTHER
Group type: OTHER
Intervention: Body App
Description: Participants will indicate areas of concern on a virtual manikin using an electronic online interface. Body measurements will also be collected.

Intervention type: OTHER
Group type: OTHER
Intervention: Body App
Description: Participants will indicate areas of concern on a virtual manikin using an electronic online interface. Body measurements will also be collected.
Study: NCT04511208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Without cooling vest
Description: Evaluate surgeons' mean-body temperature and cognitive performance without cooling vest.
Study: NCT03807440

Intervention type: DRUG
Intervention: Empagliflozin
Description: Empagliflozin

Intervention type: DRUG
Intervention: Sodium Glucose Transporter 2 inhibitor
Description: Sodium Glucose Transporter 2 inhibitor

Intervention type: DRUG
Intervention: Dipeptidyl-peptidase 4 inhibitor
Description: Dipeptidyl-peptidase 4 inhibitor

Intervention type: DRUG
Intervention: Glucagon-like peptide 1 agonist
Description: Glucagon-like peptide 1 agonist
Study: NCT03575351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: JCAR017
Description: JCAR017
Study: NCT01170741

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Tailored Cue Cards
Description: The proposed intervention uses education to increase knowledge and skill building to influence behavior-specific self-efficacy and outcome expectations. In addition to providing general information regarding drug use and diseases, the cue-cards include information that is designed to raise awareness regarding perceived threats (perceived susceptibility and perceived severity) related to HIV and other STIs and blood-borne infections, which increases motivation to reduce risk behaviors. The cue-cards also provide information regarding risk reduction strategies. The cue-cards also contain instructions on how to anticipate and avoid risky situations (e.g., using alcohol or drugs prior to sex). This information is augmented with an exercise that involves modeling and guided practice. This combination of information and exercises modifies outcome expectations by increasing confidence (i.e., perceived self-efficacy) that a protective action can be performed
Study: NCT03412058

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: To be performed prior to anti-PD1/PD-L1 treatment initiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: To be performed prior to anti-PD1/PD-L1 treatment initiation
Study: NCT01758471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Acarbose 50mg per pill 100mg to 150mgtid p.o.（oral） for 3 month
Study: NCT03412058

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: To be performed prior to anti-PD1/PD-L1 treatment initiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: To be performed after 42 (±3) days of anti-PD1 or PD-L1 treatment in consenting patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: To be performed after 42 (±3) days of anti-PD1 or PD-L1 treatment in consenting patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: To be performed after 42 (±3) days of anti-PD1 or PD-L1 treatment in consenting patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: To be performed at disease progression if medically feasible

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: To be performed at disease progression if medically feasible

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: To be performed at disease progression if medically feasible
Study: NCT00209690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: X mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 800 mg/m2, CIV (conti.in the vein) on day 1\~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT02690467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insupen G34x3,5mm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insupen G32x4mm
Study: NCT00677963

Intervention type: DRUG
Group type: OTHER
Intervention: sulphur hexafluoride, gadopentate dimeglumine
Description: CE-US, using 2 x 2.4 ml sulphur hexafluoride and MRI, using 1 x 0.2 ml/kg gadopentate dimeglumine
Study: NCT03435029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Program (REHACOP)
Description: The REHACOP group received cognitive remediation sessions 3 times per week for 3 months in 60 minute per session. The rehabilitation consisted of 39 sessions divided into: attention and concentration unit (sustained, selective, alternating, and divided attention) 4 weeks; learning and memory unit (verbal and visual memory and learning strategies) 3 weeks; language (verbal fluency, syntax, grammar, vocabulary, and comprehension) 3 weeks; and executive functioning (objectives planning and attainment, verbal reasoning, categorization, and conceptualization). In addition, processing speed was trained transversely during all the sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: The control group received occupational group activities (reading the newspaper, drawing, singing or doing crafts) with the same frequency and format as the experimental group.
Study: NCT04576351

Intervention type: OTHER
Intervention: Observation
Description: The study is a multi-center Norwegian prospective observational clinical study of the occurence of neurological, neuropsychological and psychiatric manifestations and sequelae in patients with COVID-19 at 6- and 12-months follow-up.

Intervention type: OTHER
Intervention: Observation
Description: The study is a multi-center Norwegian prospective observational clinical study of the occurence of neurological, neuropsychological and psychiatric manifestations and sequelae in patients with COVID-19 at 6- and 12-months follow-up.
Study: NCT03847337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth-Screening Tool for Autism in Toddlers (STAT)
Description: Structured autism screening tool

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth-Screening Tool for Autism in Toddlers (STAT)
Description: Structured autism screening tool

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth-Autism Spectrum Disorder-Pediatrics (ASD-PEDS)
Description: Semi-structured autism screening tool

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth-Autism Spectrum Disorder-Pediatrics (ASD-PEDS)
Description: Semi-structured autism screening tool
Study: NCT00569920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: IV dexamethasone 0,15 mg/kg bodyweight. Single-dose bolus injection after start of anesthesia. Medication is opened and administrated to the patient from a coded ampoule by the physician. The medication is diluted in such a way that 1 mL is equivalent to 10 kg body weight (1,5 mg/mL).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: natriumchloride 0,9%
Description: iv natriumchloride 0,9% (placebo). 1 mL is equivalent to 10 kg body weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: IV dexamethasone 0,30 mg/kg body weight. Drug diluted to 3,0 mg/mL and administrated in same way as arm 2.
Study: NCT04797975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KDS-1000
Description: Non-randomized part of study:~* At the beginning of each dose level (Cohort), 3 patients will receive KDS-1000. These initial patients will be enrolled in a staggered manner to ensure detection of any early safety signals.~Randomized part of the study (Can start when there are no safety concerns in the non-randomized cohorts):~* Cohort 1: Low Dose, 2x10E8 cells/dose~* Cohort 2: High Dose, 1x10E9 cells/dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Normal Saline
Study: NCT03955029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Interval training
Description: heating up 7 minutes at 15 watt, then alternating 30% of the maximum power reached by the patient at Vo2 max for 3 minutes and first peak at 40% of max power, second at 45%, third at 50%, fourth at 55 % and fifth to 60%, then return to calm 3 minutes at 15 watt. Total duration of the endurance session: 30 minutes. The powers of the peak will be modeled according to the Borg (if \<6, increase by 5 watt the value of each peak at the next session).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Interval training
Description: warm up 7 minutes at 15 watt, then alternating between plateau at 30% of the max power reached by the patient at VO2 max for 3 minutes and peak at 60% for 1 minute, return to calm 3 minutes at 15 watts. Total duration of the endurance session: 30 minutes. The power of the peak will be modeled according to the Borg (if \<6, increase by 5 watt the value of each peak at the next session)
Study: NCT00209690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Briplatin
Description: 15 mg/m2, IV (in the vein) on day 1\~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT02911909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delfi
Description: Patients will receive standard of care post-operative ACL reconstruction rehabilitation plus the Delfi moderated blood flow restriction therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: Patients will receive standard of care post-operative ACL reconstruction rehabilitation
Study: NCT02199977

Intervention type: OTHER
Group type: OTHER
Intervention: Free Malaria Rapid Diagnostic Test
Description: Malaria RDT is offered free if patients choose to be tested

Intervention type: OTHER
Group type: OTHER
Intervention: Free Malaria Rapid Diagnostic Test
Description: Malaria RDT is offered free if patients choose to be tested

Intervention type: OTHER
Group type: OTHER
Intervention: Conditional ACT voucher
Description: Participants will be eligible to receive a drug subsidy for a set amount (in the form of a voucher) conditional on a positive malaria test. When a conditional subsidy is offered, it is valid for use on a Green Leaf approved malaria drug.

Intervention type: OTHER
Group type: OTHER
Intervention: Conditional ACT voucher
Description: Participants will be eligible to receive a drug subsidy for a set amount (in the form of a voucher) conditional on a positive malaria test. When a conditional subsidy is offered, it is valid for use on a Green Leaf approved malaria drug.
Study: NCT04401631

Intervention type: DEVICE
Intervention: Blood Collection
Description: Between-Run Reproducibility K3-EDTA venous whole blood 3 mL 1 venous draw~Operator-to-operator imprecision (abioSCOPE) K3-EDTA capillary whole blood 0.05 mL/draw; 0.15 mL total 3 finger sticks (3 different fingers)~Sample type comparison (abioSCOPE) K3-EDTA capillary whole blood, venous serum, venous K3-EDTA plasma 0.35 mL (finger stick), 9 mL of whole blood to get a minimum of 3 mL of serum and 9 mL of whole blood K3-EDTA to get a minimum of 3 mL of plasma 1 finger stick; 1 venous draw into serum tube (9 mL) and 1 venous draw into K3-EDTA plasma tube (9 mL), in total 18 mL~Method comparison (abioSCOPE and ImmunoCAP/Phadia) K3-EDTA capillary whole blood, venous K3-EDTA plasma 0.05 mL (finger stick), 9 mL of whole blood to get a minimum of 3 ml of plasma 1 finger stick; 1 venous draw into K3-EDTA plasma tube (9 mL tube)
Study: NCT04444141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: The subjects will receive AK104 till disease progression or for a maximum of 24 months.
Study: NCT02598999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX-009
Description: Solution for inhalation administered through nebulization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX-009
Description: Solution for inhalation administered through nebulization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSCN-
Description: Solution for inhalation administered through nebulization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSCN-
Description: Solution for inhalation administered through nebulization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bLF
Description: Solution for inhalation administered through nebulization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bLF
Description: Solution for inhalation administered through nebulization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for inhalation administered through nebulization, Sodium Chloride 0.9%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for inhalation administered through nebulization, Sodium Chloride 0.9%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for inhalation administered through nebulization, Sodium Chloride 0.9%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for inhalation administered through nebulization, Sodium Chloride 0.9%
Study: NCT00862277

Intervention type: BIOLOGICAL
Intervention: Menactra®
Description: 0.5 mL, Intramuscular (from a previous study)
Study: NCT02199977

Intervention type: OTHER
Group type: OTHER
Intervention: Malaria Rapid Diagnostic test for a charge
Description: Participants can receive a malaria RDT for a set amount (i.e., not for free).

Intervention type: OTHER
Group type: OTHER
Intervention: Malaria Rapid Diagnostic test for a charge
Description: Participants can receive a malaria RDT for a set amount (i.e., not for free).
Study: NCT00862277

Intervention type: BIOLOGICAL
Intervention: Menomune®
Description: 0.5 mL, Intramuscular (from a previous study)
Study: NCT01964560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Pharmaceutical form: oral solution~Concentration: 1 mg/kg - 6 mg/kg BID (2 mg/kg/day - 12 mg/ kg/day)~Route of administration: oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Pharmaceutical form: tablet~Concentration: 50 mg - 300 mg BID (100 mg/day - 600 mg/day)~Route of administration: oral use
Study: NCT03690999

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic supplement
Description: Prebiotic supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic supplement
Description: Prebiotic supplement
Study: NCT02935543

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART 19
Description: CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion. Subjects will receive 1-5 x 10\^8 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction: 1-5x10\^7 CART19 cells, Day 2, 30% fraction: 3x10\^7-1.5x10\^8 CART19 cells, Day 3, 60% fraction: 6x10\^7-3x10\^8 CART19 cells
Study: NCT01843478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Collected HPV Test
Description: The HPV self-collected test is followed by results counseling by phone when the result is available (usually 2-3 weeks). Women are encouraged to have Pap testing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Study: NCT03705624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Community Case Management (CCM)
Description: Enhanced Community Case Management for malaria (CCM) involving weekly active screening for fever using a research-grade thermometer by a trained health worker. A measured temperature ≥37.5°C or reported fever in the last 24 hours will prompt screening with a conventional rapid diagnostic test (RDT). RDT positive individuals will be treated with AL according to national guidelines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Community Case Management (CCM)
Description: Enhanced Community Case Management for malaria (CCM) involving weekly active screening for fever using a research-grade thermometer by a trained health worker. A measured temperature ≥37.5°C or reported fever in the last 24 hours will prompt screening with a conventional rapid diagnostic test (RDT). RDT positive individuals will be treated with AL according to national guidelines
Study: NCT03210077

Intervention type: DEVICE
Intervention: Monitoring
Description: Monitoring
Study: NCT04730323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Participants received an initial dose calculated as per the body weight (8mg/kg) maximum 800mg/dose) over 1 hour, followed by up to three additional doses if required as per the response after the first dose with 8 hours intervals. Predefined Parameters of disease severity were assessed 12 to 24 hourly. Injection Paracetamol 1g was administered before infusion. The response of the participants after Tocilizumab administration was recorded based on clinical parameters (Oxygen requirement, Fever, Need for invasive positive pressure ventilation), biochemical parameters (D-dimers, C-reactive protein (CRP), Ferritin, Lactate dehydrogenase (LDH) levels), Chest X-ray findings, and Repeated PCR test for COVID-19. Any side effects noted after administration of TOCILIZUMAB were recorded.~Any side effects noted after administration of TCZ/ Corticosteroid were recorded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants received an initial dose calculated as per the body weight (8mg/kg) maximum 800mg/dose) over 1 hour, followed by up to three additional doses if required as per the response after the first dose with 8 hours intervals. Predefined Parameters of disease severity were assessed 12 to 24 hourly. Injection Paracetamol 1g was administered before infusion. The response of the participants after Tocilizumab administration was recorded based on clinical parameters (Oxygen requirement, Fever, Need for invasive positive pressure ventilation), biochemical parameters (D-dimers, C-reactive protein (CRP), Ferritin, Lactate dehydrogenase (LDH) levels), Chest X-ray findings, and Repeated PCR test for COVID-19. Any side effects noted after administration of TOCILIZUMAB were recorded.~Any side effects noted after administration of TCZ/ Corticosteroid were recorded.
Study: NCT04427592

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: trans-vaginal and trans-abdominal ultrasound using different modalities such as grey-scale, Doppler, multi-planer mode
Study: NCT03705624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monthly Screening and Treatment (MSAT)
Description: Monthly Screening and Treatment (MSAT) regardless of symptoms with a conventional RDT. Screening will be performed by research staff with 25-35 days between screening rounds; RDT positive individuals will be treated with AL according to national guidelines.
Study: NCT03639532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: COC THA
Description: standard total hip arthroplasty is done, with ceramic on ceramic for the bearing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: COP THA
Description: standard total hip arthroplasty is done, with ceramic on highly cross linked polyethylene for the bearing.
Study: NCT03845465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect + Education
Description: Adolescents will complete a health behavior contract and receive an educational packet at baseline. Adolescents will complete a positive affect interview at baseline. They will receive automated text messages 5 days/week for 8 weeks. Messages will be tailored to include adolescents' responses to the baseline interview, including reminders to engage in gratitude and self-affirmation. Additionally, to induce positive mood they will be texted gift cards codes valued at $5.00. Further, caregivers will be asked to provide weekly positive affirmations to their adolescents, focused on non-diabetes strengths.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Adolescents will complete a health behavior contract and receive an educational packet with information about diabetes management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Adolescents will complete a health behavior contract and receive an educational packet with information about diabetes management.
Study: NCT00731432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transmucosal Herbal Periodontal Patch (THPP)
Description: Patch applied to oral gingiva